Article
CCN5 Activation by free or encapsulated-EGCG is required to Render Triple-negative breast cancer cell Viability and Tumor Progression
2022-03-30
Abstract excerpt
<h4>Background: </h4> and Purpose: Epigallocatechin-3-gallate (EGCG) has been considered an anticancer agent despite conflicting and discrepant bioavailability views. EGCG impairs the viability and self-renewal capacity of triple-negative breast cancer (TNBC) cells and makes them sensitive to estrogen via activating ER-α. Surprisingly, the mechanism of EGCG’s action on TNBC cells remains unclear. CCN5/WISP-2 is a...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- b17704a5-f180-5a1a-908f-9deb9bb8930d
- DOI
- 10.22541/au.164864795.55156696/v1
